Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A pilot study of pembrolizumab in combination with decitabine and hypofractionated index lesion radiation in pediatric and young adult patients with relapsed and refractory solid tumors or lymphoma.
Authors
Brian Turpin
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Brian Turpin, Ralph Vatner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Novel Clinical Trial Designs
Clinical Trial Registration Number
NCT03445858
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr TPS25)
DOI
10.1200/JCO.2019.37.8_suppl.TPS25
Abstract #
TPS25
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand
Poster
2017 ASCO Annual Meeting
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1+ advanced, relapsed, or refractory solid tumor or lymphoma.
First Author: Birgit Geoerger
Poster
2017 ASCO Annual Meeting
Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.
First Author: David Stephen Shulman
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang